Efficacy of Early Rhythm Control in AF With TR Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSamsung Medical Center
About this trial
Atrial fibrillation is frequently accompanied by tricuspid regurgitation and may contribute to right atrial and tricuspid annular remodeling, leading to progression of tricuspid regurgitation and adverse clinical outcomes. However, whether early rhythm control improves prognosis in patients with atrial fibrillation and tricuspid regurgitation remains unclear. This study will compare early rhythm control with usual care in these patients, using a composite outcome of cardiac death, heart failure admission, stroke, and tricuspid valve surgery.
Eligibility criteria
Qualifiers
Patients with concomitant atrial fibrillation and tricuspid regurgitation.
Disqualifiers
Patients with a history of valvular surgery
Patients with congenital heart disease
Patients with primary pulmonary hypertension
Patients with CIED implantation prior to the diagnosis of tricuspid regurgitation
Trial design
Treatments tested in this trial
- Anti-arrhythmic drugs for rhythm control
- DC cardioversion, catheter ablation for rhythm control
- Usual care
Treatment groups
5,800 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov